Roivant Sciences: Fortress Balance Sheet, Big Pipeline Bets, and Governance Red Flags
Overview
Roivant Sciences Ltd. is a biopharma innovator with a distinctive 'Vant' model, rapidly advancing and monetizing clinical-stage assets through nimble, focused subsidiaries. Major recent asset sales have transformed the company into a fortress of liquidity, with $4.5B in cash and a valuable stake in Immunovant, alongside a concentrated late-stage pipeline (Brepocitinib, Mosliciguat) and a set of high-risk, high-reward contingent assets (notably LNP patent litigation and milestones from Organon). The company's sum-of-the-parts valuation is underpinned by cash and marketable equity holdings, with considerable optionality from its pipeline and lawsuit outcomes. However, governance concerns—particularly significant insider selling versus aggressive buybacks—temper the otherwise compelling story.